Immunoprecise Antibodies Stock Performance
| IPA Stock | USD 0.35 0.02 6.06% |
Immunoprecise Antibodies has a performance score of 1 on a scale of 0 to 100. The company retains a Market Volatility (i.e., Beta) of 0.75, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, Immunoprecise Antibodies' returns are expected to increase less than the market. However, during the bear market, the loss of holding Immunoprecise Antibodies is expected to be smaller as well. Immunoprecise Antibodies right now retains a risk of 7.02%. Please check out Immunoprecise Antibodies treynor ratio and the relationship between the skewness and day typical price , to decide if Immunoprecise Antibodies will be following its current trending patterns.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Immunoprecise Antibodies are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. Despite somewhat inconsistent basic indicators, Immunoprecise Antibodies may actually be approaching a critical reversion point that can send shares even higher in April 2025. ...more
| Begin Period Cash Flow | 8.4 M |
Immunoprecise |
Immunoprecise Antibodies Relative Risk vs. Return Landscape
If you would invest 37.00 in Immunoprecise Antibodies on December 5, 2024 and sell it today you would lose (2.00) from holding Immunoprecise Antibodies or give up 5.41% of portfolio value over 90 days. Immunoprecise Antibodies is generating 0.1337% of daily returns assuming volatility of 7.0204% on return distribution over 90 days investment horizon. In other words, 62% of stocks are less volatile than Immunoprecise, and above 98% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Immunoprecise Antibodies Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Immunoprecise Antibodies' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Immunoprecise Antibodies, and traders can use it to determine the average amount a Immunoprecise Antibodies' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.019
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | IPA |
| Negative Returns |
Estimated Market Risk
| 7.02 actual daily | 62 62% of assets are less volatile |
Expected Return
| 0.13 actual daily | 2 98% of assets have higher returns |
Risk-Adjusted Return
| 0.02 actual daily | 1 99% of assets perform better |
Based on monthly moving average Immunoprecise Antibodies is performing at about 1% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Immunoprecise Antibodies by adding it to a well-diversified portfolio.
Immunoprecise Antibodies Fundamentals Growth
Immunoprecise Stock prices reflect investors' perceptions of the future prospects and financial health of Immunoprecise Antibodies, and Immunoprecise Antibodies fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Immunoprecise Stock performance.
| Return On Equity | -0.66 | ||||
| Return On Asset | -0.14 | ||||
| Profit Margin | (1.16) % | ||||
| Operating Margin | (0.46) % | ||||
| Current Valuation | 24.55 M | ||||
| Shares Outstanding | 45.77 M | ||||
| Price To Book | 0.69 X | ||||
| Price To Sales | 0.63 X | ||||
| Revenue | 24.52 M | ||||
| EBITDA | (22.95 M) | ||||
| Cash And Equivalents | 19.24 M | ||||
| Cash Per Share | 0.77 X | ||||
| Total Debt | 13.68 M | ||||
| Debt To Equity | 0.02 % | ||||
| Book Value Per Share | 1.08 X | ||||
| Cash Flow From Operations | (4.25 M) | ||||
| Earnings Per Share | (0.75) X | ||||
| Total Asset | 59.99 M | ||||
| Retained Earnings | (100.27 M) | ||||
About Immunoprecise Antibodies Performance
By analyzing Immunoprecise Antibodies' fundamental ratios, stakeholders can gain valuable insights into Immunoprecise Antibodies' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Immunoprecise Antibodies has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Immunoprecise Antibodies has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and provision of related services in the United States, Canada, Europe, Australia, and internationally. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada. Immunoprecise Antibodies is traded on NASDAQ Exchange in the United States.Things to note about Immunoprecise Antibodies performance evaluation
Checking the ongoing alerts about Immunoprecise Antibodies for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Immunoprecise Antibodies help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Immunoprecise Antibodies had very high historical volatility over the last 90 days | |
| Immunoprecise Antibodies has some characteristics of a very speculative penny stock | |
| Immunoprecise Antibodies has a very high chance of going through financial distress in the upcoming years | |
| The company reported the last year's revenue of 24.52 M. Reported Net Loss for the year was (27.18 M) with profit before taxes, overhead, and interest of 12.1 M. | |
| Immunoprecise Antibodies has about 19.24 M in cash with (4.25 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.77, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Immunoprecise Antibodies has a frail financial position based on the latest SEC disclosures |
- Analyzing Immunoprecise Antibodies' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Immunoprecise Antibodies' stock is overvalued or undervalued compared to its peers.
- Examining Immunoprecise Antibodies' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Immunoprecise Antibodies' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Immunoprecise Antibodies' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Immunoprecise Antibodies' stock. These opinions can provide insight into Immunoprecise Antibodies' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Immunoprecise Stock analysis
When running Immunoprecise Antibodies' price analysis, check to measure Immunoprecise Antibodies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunoprecise Antibodies is operating at the current time. Most of Immunoprecise Antibodies' value examination focuses on studying past and present price action to predict the probability of Immunoprecise Antibodies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunoprecise Antibodies' price. Additionally, you may evaluate how the addition of Immunoprecise Antibodies to your portfolios can decrease your overall portfolio volatility.
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world |